This disclosure relates to antigenic OspA polypeptides and their use in eliciting antibodies against OspA. Also disclosed are antigenic polypeptides comprising an OspA polypeptide and a ferritin protein.

The present invention provides new pharmaceutical and vaccine compositions comprising Treponema spp. bacterins, supplemented with antigens from Treponema spp. or other digital dermatitis causative pathological agents such as but not limited to D. nodosus or F. necrophorum, for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. The present invention also identifies Treponema pedis and Treponema phagedenis as two of the etiologic agents of digital dermatitis (DD) in mammals, in particular ungulate digital dermatitis. The invention therefore also provides isolated cultures of Treponema pedis and Treponema phagedenis for effectively immunizing susceptible mammals, preferably ungulates, against DD, in particular against bovine digital dermatitis. In addition, the present invention provides methods of diagnosing DD by detecting infection with a series of specific Treponema antigens.

This invention relates to variants of Cas12a nucleases having altered protospacer adjacent motif recognition specificity. The invention further relates to methods of making CRISPR-CAS nuclease variants and methods of modifying nucleic acids using the variants.

This invention relates to variants of Cas12a nucleases having altered protospacer adjacent motif recognition specificity. The invention further relates to methods of making CRISPR-CAS nuclease variants and methods of modifying nucleic acids using the variants.

Compositions and methods for the detection and identification of Tick-Borne Relapsing Fever Borrelia sp. antibodies.

The present invention relates to Brachyspira hyodysenteriae strains and their use in diagnosis or treatment. In addition, the invention provides a vaccine against diarrheal disease, in particular swine dysentery.

The present invention relates to Brachyspira hyodysenteriae strains and their use in diagnosis or treatment. In addition, the invention provides a vaccine against diarrheal disease, in particular swine dysentery.

Two Borrelia burgdorferi recombinant proteins were expressed in E. coli. These two proteins were generated from (a) the full length dbpA gene combined with the invariable region 6 of the VlsE gene (dbpA/C6), and (b) the full length OspC gene combined with the coding sequence for amino acids 1-121 of the E. coli maltose binding protein gene (OspC/MBP). Methods of using these recombinant proteins for detecting anti-Borrelia burgdorferi antibodies in patient sera and diagnosis of Lyme Disease are described.

Two Borrelia burgdorferi recombinant proteins were expressed in E. coli. These two proteins were generated from (a) the full length dbpA gene combined with the invariable region 6 of the VlsE gene (dbpA/C6), and (b) the full length OspC gene combined with the coding sequence for amino acids 1-121 of the E. coli maltose binding protein gene (OspC/MBP). Methods of using these recombinant proteins for detecting anti-Borrelia burgdorferi antibodies in patient sera and diagnosis of Lyme Disease are described.

The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.